Applying arterial enhancement fraction (AEF) texture features to predict the tumor response in hepatocellular carcinoma (HCC) treated with Transarterial chemoembolization (TACE)

Table 1 Baseline of the enrolled cases

Characteristics	Improved	Un-improved	p	Un-worsened	Worsened	p
Gender	18^Male/4^Female	19^Male/4^Female	0.945	27^Male/4^Female	10^Male/4^Female	0.203
Age (years)	63.00 ± 9.18	60.09 ± 8.98	0.288	61.87 ± 9.14	60.71 ± 9.28	0.698
Weight (kg)	66.91 ± 11.98	70.74 ± 12.81	0.307	70.65 ± 11.87	64.93 ± 13.16	0.155
Hepatitis type	15^B/7^Others	19^B/4^Others	0.260	22^B/9^Others	12^B/2^Others	0.287
Alcoholic history	11^Yes/11^No	10^Yes/13^No	0.661	15^Yes/16^No	6^Yes/8^No	0.731
HCC family history	4^Yes/18^No	6^Yes/17^No	0.524	4^Yes/27^No	6^Yes/8^No	0.025
Tumor stage*	12^A/7^B/3^C	8^A/11^B/4^C	0.596	15^A/12^B/4^C	5^A/6^B/3^C	0.343
Child-Pugh score	5.55 ± 0.67	5.70 ± 0.88	0.523	5.61 ± 0.72	5.64 ± 0.93	0.906
Ammonia (mmol/L)	56.67 ± 18.44	73.35 ± 18.68	0.004	62.86 ± 21.16	70.36 ± 17.49	0.223
Albumin (g/L)	37.42 ± 6.06	35.98 ± 6.12	0.431	37.08 ± 5.63	35.80 ± 7.07	0.517
Total bilirubin (mmol/L)	21.43 ± 8.27	18.71 ± 1.30	0.335	21.38 ± 8.39	17.06 ± 10.93	0.154
Prothrombin time (S)	13.10 ± 1.63	12.63 ± 1.47	0.315	13.09 ± 1.55	12.34 ± 1.47	0.137
AFP (μg/L)	78.04^{(2.10 ~ 11,041.00)}	26.05^{(2.48 ~ 4466.00)}	0.586	78.04^{(2.10 ~ 11,041.00)}	26.03^{(2.48 ~ 4466.00)}	0.364

Note: Description of the baseline clinical data using Mean ± SD) for continuous variables that conform to normal distribution, Median^(Range) for continuous variables that don’t conform to normal distribution, and the actual number for categorical variables. Correspondingly, the statistical assessment applied Independent sample t test, Mann-Whitney U test, and Chi-squared test respectively. “*”: Tumor stages were judged based on Barcelona staging system

ISSN: 1470-7330